Total Marrow and Lymphoid Irradiation

RADIATION5 trials

Conditions

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia With Complex KaryotypeMyelodysplastic Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelodysplastic SyndromesRecurrent Acute Myeloid Leukemia

Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

RecruitingNCT06195891

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2024-05-24End: 2030-03-22Target: 33Updated: 2026-04-29

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

RecruitingNCT06287944

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2025-07-01End: 2028-05-19Target: 15Updated: 2026-07-31

Phase 2

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

RecruitingNCT07582172

City of Hope Medical CenterAcute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome +8

Start: 2027-04-05End: 2029-04-05Target: 35Updated: 2026-08-20

Unknown Phase

Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia

NCT03408210

Affiliated Hospital to Academy of Military Medical SciencesAcute Leukemia, Myelodysplastic Syndromes

Start: 2014-03-31End: 2022-08-31Target: 191Updated: 2018-01-23

Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia

NCT03408223

Affiliated Hospital to Academy of Military Medical SciencesAcute Leukemia

Start: 2014-03-31End: 2022-12-31Target: 100Updated: 2018-01-23

Related Papers

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia